Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXM01 in metastatic colorectal cancer
NCT02718430Phase 1Completed
- Sponsor
- Vaximm
- Start
- Feb 2016
- Primary completion
- Mar 2018
- Modality
- DNA Vaccines, Live Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vxm01 in colorectal cancer (CRC), sponsored by Vaximm. Primary endpoint: Safety and tolerability taking into account treatment-limiting toxicities (TLTs) at 18 months. Started Feb 2016; status: completed.
02
Drugs
vxm01
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02718430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718430.